List of Excipients in Branded Drug PIOGLITAZONE HYDROCHLORIDE

« Back to Dashboard

Generic Drugs Containing PIOGLITAZONE HYDROCHLORIDE

Company	Ingredient	NDC	Excipient
Aphena Pharma Solutions - Tennessee LLC	pioglitazone hydrochloride	43353-326	CARBOXYMETHYLCELLULOSE CALCIUM
Aphena Pharma Solutions - Tennessee LLC	pioglitazone hydrochloride	43353-326	HYDROXYPROPYL CELLULOSE
Aphena Pharma Solutions - Tennessee LLC	pioglitazone hydrochloride	43353-326	LACTOSE MONOHYDRATE
Aphena Pharma Solutions - Tennessee LLC	pioglitazone hydrochloride	43353-326	MAGNESIUM STEARATE
A-S Medication Solutions	pioglitazone hydrochloride	50090-1319	CARBOXYMETHYLCELLULOSE CALCIUM

What are the Most Frequently-Used Excipients in PIOGLITAZONE HYDROCHLORIDE?

# Of NDCs	Excipient
4	CALCIUM CARBOXYMETHYL CELLULOSE
31	CARBOXYMETHYLCELLULOSE CALCIUM
2	CELLULOSE, MICROCRYSTALLINE
37	HYDROXYPROPYL CELLULOSE
37	LACTOSE MONOHYDRATE

Last updated: October 20, 2026

ecutive summary: Pioglitazone hydrochloride is a mature, genericized antidiabetic active ingredient with limited molecule-level exclusivity and established immediate-release tablet technology. The strongest commercial opportunities are not new-compound patents. They are differentiated excipient systems that improve dose uniformity, tablet robustness, dissolution consistency, manufacturability, stability, and fixed-dose combination performance. The main target products are pioglitazone-metformin and pioglitazone-glimepiride tablets, plus lower-cost, high-throughput formulations for emerging markets.

Pioglitazone Hydrochloride Excipient Strategy and Commercial Opportunities

What is the current market and regulatory status of pioglitazone hydrochloride?

Pioglitazone hydrochloride is an oral thiazolidinedione approved for improving glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. In the United States, it is marketed primarily as generic immediate-release tablets in 15 mg, 30 mg, and 45 mg strengths.[1]

The original branded product, Actos, was developed by Takeda Pharmaceuticals. FDA-approved pioglitazone products include:

Product category	Typical dosage forms	Commercial status
Pioglitazone hydrochloride	15 mg, 30 mg, 45 mg tablets	Generic competition
Pioglitazone/metformin hydrochloride	Immediate-release tablets	Generic competition
Pioglitazone/glimepiride	Immediate-release tablets	Generic competition
Actos	Immediate-release tablets	Legacy brand; generic substitution dominates

Pioglitazone is administered once daily, with or without food. Its primary formulation challenge is not rapid drug release. It is consistent delivery of a relatively low-dose, hydrophobic active ingredient across multiple tablet strengths and manufacturing sites.

FDA labeling carries important safety warnings involving congestive heart failure, edema, fractures, and bladder cancer risk.[1] These warnings affect commercial positioning and can limit premium pricing for a differentiated excipient platform unless the formulation provides a measurable manufacturing, stability, or adherence benefit.

What patents protect pioglitazone hydrochloride?

The core U.S. composition-of-matter protection for pioglitazone expired years ago. The original Actos patent estate therefore does not create a current barrier to standard generic tablet development.

Patent or protection category	Commercial relevance
Core pioglitazone compound patent	Expired
Original immediate-release tablet technology	Expired or commercially obsolete
Historical method-of-use patents	Generally expired; limited current blocking value
Pediatric exclusivity	Historical and expired
Current FDA product exclusivity	No meaningful exclusivity for standard generic pioglitazone tablets
New formulation patents	Potentially available only for genuinely differentiated systems

The Orange Book remains the principal FDA source for listed patents and regulatory exclusivity associated with approved drug products.[2] For a new pioglitazone formulation, patent protection would need to focus on a specific composition, manufacturing process, particle engineering approach, stability profile, or clinically relevant delivery characteristic.

When does pioglitazone lose exclusivity?

Pioglitazone lost practical U.S. market exclusivity after expiry of the original compound and product-related patent protections. Generic manufacturers have marketed pioglitazone hydrochloride tablets for many years. A new entrant therefore faces abbreviated new drug application competition rather than an innovator-style exclusivity period.

A new excipient system could receive patent protection, but FDA approval alone would not create broad market exclusivity. The patent claims would need to cover a narrow technical feature that competitors cannot easily design around.

What excipients are used in pioglitazone hydrochloride tablets?

Approved pioglitazone tablets use conventional oral solid-dose excipients. The Actos label identifies inactive ingredients including lactose monohydrate, hydroxypropyl cellulose, carboxymethylcellulose calcium, and magnesium stearate.[3] Generic labels vary by manufacturer and may include microcrystalline cellulose, croscarmellose sodium, hypromellose, colloidal silicon dioxide, povidone, talc, and additional lubricants or film-coating materials.[4]

A representative formulation architecture is:

Formulation function	Candidate excipients	Strategic purpose
Diluent	Lactose monohydrate, microcrystalline cellulose, mannitol, dibasic calcium phosphate	Tablet mass, compressibility, cost control
Binder	Hydroxypropyl cellulose, povidone, pregelatinized starch	Granule strength and content uniformity
Disintegrant	Croscarmellose sodium, sodium starch glycolate, crospovidone	Consistent tablet breakup
Glidant	Colloidal silicon dioxide	Powder flow and die filling
Lubricant	Magnesium stearate, sodium stearyl fumarate	Ejection force and tooling protection
Film coating	Hypromellose, polyvinyl alcohol, polyethylene glycol, titanium dioxide	Appearance, handling, identification
pH or microenvironment modifier	Selected buffers or alkaline excipients	Dissolution and stability control
Taste-masking aid	Polymer coating or ion-complexing system	Relevant mainly to dispersible or pediatric formats

The commercial value of each excipient depends on the manufacturing process. A formulation optimized for direct compression may not transfer efficiently to wet granulation. A formulation using lactose may require different moisture controls from one using anhydrous dibasic calcium phosphate or mannitol.

How should an excipient strategy address pioglitazone’s physicochemical properties?

Pioglitazone hydrochloride is a low-dose active with limited aqueous solubility characteristics that can make dissolution sensitive to particle size, wetting, compression force, and tablet porosity. The hydrochloride salt improves handling relative to the free base but does not eliminate formulation sensitivity.

The principal formulation risks are:

1. Poor distribution of a low-dose active within a large excipient matrix.
2. Over-lubrication, which can slow wetting and dissolution.
3. Excessive compression, which can reduce tablet porosity.
4. Moisture-driven changes in granule strength or dissolution.
5. Scale-up differences in blending and lubrication time.
6. Dissolution variability among 15 mg, 30 mg, and 45 mg strengths.

A practical strategy is to prioritize content uniformity and dissolution robustness before adding complex solubilization technology. The standard product is an immediate-release tablet. A high-cost lipid formulation, amorphous dispersion, or nanocrystal system may improve exposure but would face a difficult commercial case unless it demonstrates a clinically relevant benefit or a major manufacturing advantage.

Which excipients are most commercially attractive?

Microcrystalline cellulose, lactose, low-substituted hydroxypropyl cellulose, crospovidone, croscarmellose sodium, colloidal silicon dioxide, and sodium stearyl fumarate are commercially attractive because they are broadly available, familiar to regulators, and compatible with high-volume tablet production.

Specialty excipients may create higher differentiation:

• Co-processed excipients for direct compression.
• Spray-dried carriers for improved content uniformity.
• Wetting agents for dissolution control.
• Moisture-protective film coatings.
• Low-nitrite or low-peroxide excipients where impurity control is relevant.
• Functional polymers for modified release or taste masking.
• Excipient systems designed for continuous manufacturing.

The strongest opportunity is usually a platform that reduces process steps, rejects, or dissolution failures rather than one that adds a costly ingredient without changing product performance.

What formulation patents could protect a new pioglitazone product?

Patentable formulation concepts may include:

• A defined ratio of pioglitazone hydrochloride to a co-processed diluent.
• A particle-size distribution that improves content uniformity.
• A specific wet granulation endpoint and drying profile.
• A formulation with a defined dissolution profile across pH conditions.
• A low-moisture or moisture-barrier composition.
• A fixed-dose combination with improved segregation resistance.
• A tablet that maintains dissolution after accelerated stability testing.
• A manufacturing process that reduces magnesium-stearate sensitivity.
• A multiparticulate, orally disintegrating, or pediatric dosage form.

Patent strength depends on more than listing conventional excipients. Claims that recite common ingredients in broad ranges are vulnerable to obviousness and anticipation challenges. Stronger claims typically connect composition and process parameters to measurable performance, such as improved content uniformity, reduced dissolution variability, enhanced stability, or a specific pharmacokinetic profile.

How strong is the patent estate for pioglitazone excipients?

The patent estate for the original molecule is weak as a barrier to generic entry because the core rights are expired. A new excipient patent estate could be moderate if it covers a narrow, reproducible formulation with comparative data. It would be weak if it merely substitutes one conventional filler or disintegrant for another.

The best defensive structure would combine:

• Composition claims.
• Process claims.
• Product-by-process or performance claims where legally supportable.
• Claims covering multiple tablet strengths.
• Claims covering fixed-dose combinations.
• Manufacturing know-how that is not fully disclosed in the patent.

What are the best commercial opportunities for pioglitazone excipient suppliers?

Fixed-dose combination products

Pioglitazone/metformin and pioglitazone/glimepiride products create the clearest formulation opportunity. Combining multiple actives increases the risk of segregation, compression variability, assay drift, and dissolution differences.

An excipient supplier can create value through:

• Improved blend uniformity.
• Segregation-resistant granulation.
• Different release behavior for each active.
• Reduced tablet size.
• Better mechanical strength at high drug loading.
• Lower dissolution variability across strengths.

A single-tablet combination can also reduce pill burden, although the commercial value depends on physician adoption and the safety profile of pioglitazone.

Emerging-market generic manufacturing

Pioglitazone is well suited to low-cost, high-volume manufacturing. Opportunities include excipient systems that tolerate variable raw-material quality, high ambient humidity, limited process analytical technology, and less sophisticated compression equipment.

Co-processed excipients can reduce development time for manufacturers that lack extensive formulation-development infrastructure. The value proposition is strongest when the supplier can demonstrate fewer formulation iterations and reliable transfer from laboratory to commercial scale.

Direct-compression platforms

Direct compression can reduce granulation, drying, and milling costs. A co-processed excipient containing a compressible filler and functional disintegrant may support a shorter manufacturing process.

The principal technical risk is low-dose content uniformity. Pioglitazone formulations require robust blending controls, and direct compression is commercially attractive only if the excipient platform preserves uniformity across batch sizes.

Orally disintegrating and pediatric products

A pediatric or orally disintegrating dosage form could differentiate pioglitazone, but the opportunity is constrained by safety considerations and the existing once-daily tablet. Taste masking, dose flexibility, and age-appropriate clinical positioning would be required.

This is a higher-risk opportunity than conventional generic tablets. The target market is smaller, and a new dosage form may require more extensive regulatory support than a standard ANDA product.

Stability and packaging systems

Moisture-protective film coatings, bottle desiccants, and blister configurations can support products distributed in hot and humid climates. Packaging is not an excipient strategy by itself, but excipient and packaging choices should be developed together.

A formulation that achieves stable dissolution without expensive packaging has a stronger cost position than one requiring high-barrier materials and desiccants.

What FDA regulatory issues affect pioglitazone excipient selection?

For a conventional generic tablet, the formulation must meet FDA requirements for pharmaceutical equivalence and bioequivalence. Excipient changes can affect dissolution, assay, content uniformity, stability, and bioequivalence risk.[5]

Key regulatory considerations include:

• Use of excipients with established oral safety profiles.
• Compliance with FDA inactive-ingredient limits and precedent.
• Control of elemental impurities under ICH Q3D.
• Control of nitrosamines and other process-related impurities where applicable.
• Demonstration of dissolution equivalence.
• Adequate justification for novel excipients or unusually high levels.
• Compatibility with the proposed manufacturing process.
• Consistency across all tablet strengths.

A novel excipient would materially increase development and regulatory burden. For pioglitazone, established excipients with a clear regulatory history are usually more commercially rational unless the new material creates a major performance advantage.

Which companies are challenging pioglitazone, and what is the litigation status?

Pioglitazone has already experienced extensive generic competition. Major generic manufacturers and regional pharmaceutical companies have marketed pioglitazone tablets or combination products in different jurisdictions. The historic U.S. patent disputes around Actos are no longer the primary commercial issue for standard tablets.

There is no current market-wide Paragraph IV barrier that prevents routine generic entry. A future Paragraph IV dispute would more likely concern a newly patented formulation, combination, dosage form, or manufacturing process than the pioglitazone active ingredient itself.

The key litigation risks for a new product are:

• Infringement of a formulation patent.
• Invalidity attacks against narrow excipient claims.
• Patent-term differences across countries.
• Regulatory exclusivity attached to a new combination or indication.
• Trade-secret disputes over manufacturing parameters.

Settlement agreements associated with historic Actos litigation may affect specific parties or time periods, but they do not restore broad exclusivity for pioglitazone hydrochloride tablets.

How does pioglitazone compare with other oral antidiabetic drugs?

Product class	Core exclusivity position	Excipient opportunity	Commercial risk
Pioglitazone	Mature generic market	Cost, robustness, combinations	Safety perception and price pressure
Metformin	Mature generic market	High-dose tablet size and GI tolerability	Heavy competition
Sulfonylureas	Mature generic market	Modified release and dose uniformity	Hypoglycemia concerns
DPP-4 inhibitors	Some products remain branded or recently genericized	Solubility and low-dose uniformity	Patent and regulatory complexity
SGLT2 inhibitors	Stronger residual brand and formulation estates for some products	Solubility, stability, combinations	Higher patent and litigation exposure
GLP-1 products	Complex biologic or peptide delivery	Delivery-system technology	High development cost

Pioglitazone offers lower intellectual-property risk and lower development cost than newer antidiabetic products. Its disadvantage is limited pricing power. An excipient supplier should therefore compete on total manufacturing economics and regulatory execution.

What generic launch risks exist for a new pioglitazone product?

A conventional pioglitazone generic can generally be launched through an ANDA pathway if it satisfies applicable requirements. Commercial risks remain:

1. Multiple existing suppliers can compress price quickly.
2. Pharmacy substitution favors established manufacturers.
3. A new excipient may trigger additional development work.
4. Combination products may require more complex bioequivalence planning.
5. Safety concerns can limit physician demand.
6. A formulation patent may create litigation exposure.
7. Manufacturing inconsistency can produce recalls or supply interruptions.

A successful launch should target a defined gap, such as shortage resilience, a smaller tablet, improved humidity stability, simplified manufacturing, or a fixed-dose combination that reduces pill burden.

What geographic markets offer the strongest opportunity?

The United States offers regulatory clarity but intense generic price competition. Europe has a mature market with country-specific reimbursement and substitution dynamics. India, Latin America, Southeast Asia, and parts of the Middle East and Africa may offer stronger volume opportunities for cost-optimized formulations and combination products.

Geographic patent risk is generally lower for the core active than for newer antidiabetic agents, but patent status, data exclusivity, registration requirements, and local reference-product rules must be assessed by country. Excipient suppliers with regional technical support can gain an advantage because formulation transfer and regulatory documentation often determine supplier selection.

What revenue exposure does pioglitazone create for excipient suppliers?

Pioglitazone tablets use small quantities of excipients, so the active ingredient’s total volume does not automatically translate into a large excipient market. The commercial value is greater when the supplier captures a formulation platform across several products:

• Pioglitazone tablets.
• Pioglitazone/metformin combinations.
• Pioglitazone/glimepiride combinations.
• Other low-dose immediate-release tablets.
• Additional products manufactured on the same equipment.

The highest-value opportunity is therefore a repeatable excipient system with low conversion cost and broad regulatory acceptability, not a single-product premium formulation.

What is the recommended excipient development strategy?

A commercially disciplined development program should:

1. Start with a conventional immediate-release reference formulation.
2. Compare direct compression and wet granulation.
3. Screen diluent-binder systems for low-dose content uniformity.
4. Optimize disintegration without compromising dissolution.
5. Minimize lubricant sensitivity.
6. Test accelerated stability under high humidity.
7. Evaluate all three strengths early.
8. Include metformin and glimepiride combinations if platform expansion is planned.
9. Build comparative dissolution data into patent strategy.
10. Use established excipients unless a novel material produces a clear performance advantage.

The preferred first product is a robust, low-cost generic tablet. A differentiated combination or orally disintegrating formulation should follow only after the standard platform is commercially validated.

Key takeaways

• Pioglitazone hydrochloride is a mature generic active with no meaningful current molecule-level exclusivity barrier.
• Conventional immediate-release tablets remain the dominant dosage form.
• Excipient value lies in content uniformity, dissolution consistency, tablet robustness, stability, and manufacturing efficiency.
• Fixed-dose combinations offer the strongest technical differentiation.
• Co-processed excipients and direct-compression systems can reduce manufacturing cost and scale-up risk.
• New patents should claim defined compositions, processes, or measurable performance, not generic excipient substitutions.
• The United States has high regulatory clarity but intense price competition.
• Emerging markets may provide better volume opportunities for cost-optimized formulations.
• A new formulation must overcome pioglitazone’s safety-related commercial constraints to justify premium pricing.
• The strongest business case is a multi-product excipient platform covering pioglitazone and other low-dose oral tablets.

FAQs

Is pioglitazone hydrochloride still patent protected?

The core pioglitazone hydrochloride compound and original Actos protections are expired. New patents may cover specific formulations, combinations, manufacturing processes, or dosage forms.

Can a new excipient create market exclusivity for pioglitazone?

An excipient alone generally does not create FDA market exclusivity. A patent may protect a specific formulation if the composition is novel, non-obvious, and supported by technical data.

Which excipient is best for pioglitazone tablets?

No single excipient is universally optimal. Microcrystalline cellulose, lactose, hydroxypropyl cellulose, croscarmellose sodium, crospovidone, colloidal silicon dioxide, and magnesium stearate are common starting points for immediate-release development.

Are pioglitazone combination tablets more attractive than single-ingredient tablets?

They offer greater formulation differentiation because they must manage multiple actives, dose ratios, segregation, compression, and dissolution requirements. They also require more complex development and regulatory work.

Is a nanocrystal or amorphous pioglitazone formulation commercially justified?

Usually not for a standard generic tablet unless it produces a clear benefit in dissolution, bioavailability, tablet size, stability, or patient use. The technology must overcome higher manufacturing and regulatory costs in a highly competitive market.

References

1. U.S. Food and Drug Administration. (2023). Pioglitazone hydrochloride tablets: Prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.
3. Takeda Pharmaceuticals U.S.A., Inc. (2011). Actos (pioglitazone hydrochloride) tablets: Prescribing information.
4. National Library of Medicine. (2024). DailyMed: Pioglitazone hydrochloride tablet labels.
5. U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions: Pharmaceutical equivalence and bioequivalence guidance.